ENT Burden Atlas

Research attention vs disease burden in otolaryngology, 1995–2024 — a preregistered dynamic census

The 14 disease areas

Shares are compositions within the 14-area publication pool (26,544 records in 1995–99; 128,117 in 2020–24). Burden-tier areas additionally carry ABR, centroid-distance and typology results on their own pages. Attention-tier areas have no GBD-matched burden cause, so no burden quantity is computed or implied for them.

AreaShare trajectoryPublications 1995–99 Publications 2020–24Share 1995–99Share 2020–24Type / dynamics
Burden tier (with GBD-matched burden)
Otitis media2,2293,7068.4%2.9%Resolution-dilution
Hearing loss5,41121,65920.4%16.9%Constant
Laryngeal cancer8481,7633.2%1.4%Unclassified
Lip and oral cavity cancer1,19611,4124.5%8.9%Technology-ignited
Nasopharyngeal cancer2,20217,1808.3%13.4%Technology-ignited
Other pharyngeal cancer1,58910,4736.0%8.2%Unclassified
Thyroid cancer2,67516,28810.1%12.7%Unclassified
Attention tier (no GBD-matched burden; share dynamics only)
Chronic rhinosinusitis / nasal polyps (CRS)2,2668,0278.5%6.3%Share falling *
Allergic rhinitis1,6255,8456.1%4.6%Share falling
Obstructive sleep apnoea2,62715,9539.9%12.5%Share rising
Tinnitus9214,5353.5%3.5%Share stable
Vertigo1,2264,4474.6%3.5%Share stable
Cholesteatoma5301,1792.0%0.9%Share falling
Cochlear implants1,1995,6504.5%4.4%Share stable
* CRS/polyps: Terminology caveat: under a pre-frozen backup query built only from modern post-consensus terms, the CRS share change reverses (+251.0% instead of −26.6%). The apparent decline is read as terminology migration, not as a change in research volume, and is not carried as a headline conclusion.

Hearing loss is typed "constant" on dynamics only; read it together with its level, ABR 0.36 (log2 ABR −1.47) in 2020–24 — a stable misalignment, not an absence of one. "Resolution" anywhere on this site means relative share dilution inside the pool; annualised absolute DALYs rose for all seven burden-tier causes (+3.9% to +101.3%).